ALOX5AP and stroke disorder: With regard to the question of whether the rise in LTB4 triggers stroke progression or results from the cerebral ischemic insult, our data appear to indicate the former as we observed in animal studies that either inhibiting LTB4 production by a FLAP inhibitor (BAY-X1005) or blockade of BLTR with an antagonist (LY255283) resulted in a significant reduction in infarct volume.